Previous 10 | Next 10 |
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has retired all of the Company’s outst...
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that the Advanced Medical Technology Association ...
PAVmed ([[PAVM]] -6.2%) announces the closing of its previously announced underwritten public offering of about 9.8M shares of with gross proceeds of about $45M.PAVmed intends to use the net proceeds from the offering to repay all of the company’s outstanding debt, including...
NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the closing of its previously announced underwritten p...
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced the pricing of its previously announced underwritten p...
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it is commencing an underwritten public offering ...
Are These Tech Penny Stocks On Your February Watch List? The markets are definitely showing signs of uncertainty early Monday morning. Yet penny stocks – stocks under $5 – are still showing promise. Ahead of this week’s Fed-related headlines, the S&P 500 and...
PAVmed ([[PAVM]] -5.4%) posted fourth-quarter loss that missed Wall Street estimates, and announced that it intends to spin-off its majority-owned subsidiary Lucid Diagnostics into a separate public company.PAVmed will remain Lucid’s largest shareholder following any spin-off...
Announces majority-owned subsidiary Lucid Diagnostics intends to spin-off into a separate public company Lucid Diagnostics to launch major new multi-channel commercialization initiative for its EsoGuard Esophageal DNA Test Conference call to be held today at 8:30 AM EST ...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...